Abnormal responsiveness to dexamethasone-suppressed CRH test in patients with bilateral adrenal incidentalomas

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3478-3485

  Vassiliadi, D A ^a,c   Tzanela, M ^a   Tsatlidis, V ^a   Margelou, E ^a   Tampourlou, M ^a   Mazarakis, N ^b   Piaditis, G ^b   Tsagarakis, S ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; DEXAMETHASONE;

ADRENAL INCIDENTALOMA; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; ADRENAL GLAND NEOPLASMS; AGED; ENDOCRINE FUNCTION TEST; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOPHYSIOLOGY;

ADRENAL GLAND NEOPLASMS; AGED; CORTICOTROPIN-RELEASING HORMONE; DEXAMETHASONE; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY FUNCTION TESTS; PITUITARY-ADRENAL SYSTEM;

EID: 84941695936     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/JC.2015-1653     Document Type: Article

References (32)

1. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997;47(4-6):279-283.
2. VassiliadiDA,Tsagarakis S. Endocrine incidentalomas-challenges imposed by incidentally discovered lesions. Nat Rev Endocrinol. 2011;7(11):668-680.
3. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-484.
4. Vassiliadi DA, Ntali G, Vicha E, Tsagarakis S. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin Endocrinol (Oxf). 2011;74(4):438-444.
5. Vezzosi D, Libe R, Baudry C, et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with ACTH-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. J Clin Endocrinol Metab. 2012;97(11):E2063-E2069.
6. Beuschlein F, Fassnacht M, Assie G, et al. Constitutive activation of PKAcatalytic subunit in adrenal Cushing's syndrome.NEngl JMed. 2014;370(11):1019-1028.
7. Stratakis CA. cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse. Mol Cell Endocrinol. 2013;371(1-2):208-220.
8. Assie G, Libe R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013;369(22):2105-2114.
9. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf). 2010; 73(1):1-15.
10. Vassiliadi DA, Ntali G, Stratigou T, Adali M, Tsagarakis S. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine. 2011;40(3):437-444.
11. Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med. 2013; 369(22):2115-2125.
12. Imaki T, Naruse M, Takano K. Adrenocortical hyperplasia associated with ACTH-dependent Cushing's syndrome: comparison of the size of adrenal glands with clinical and endocrinological data. Endocr J. 2004;51(1):89-95.
13. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration.Anew test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. 1993;269(17):2232-2238.
14. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology. J Clin Endocrinol Metab. 1998;83(2):348-352.
15. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res. 1994;28(4):341-356.
16. Kunugi H, Ida I, Owashi T, et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitaryadrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology. 2006;31(1):212-220.
17. Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome. J Clin Endocrinol Metab. 2009;94(12):4851-4859.
18. Lee EE, Nieman LK, Martinez PE, Harsh VL, Rubinow DR, Schmidt PJ.ACTHand cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria duringGnRHagonist-induced hypogonadism and ovarian steroid replacement. J Clin Endocrinol Metab. 2012;97(6):1887-1896.
19. Sher L. Combined dexamethasone suppression/corticotropin-releasing hormone stimulation test and antidepressants: different antidepressants may produce different effects. Med Hypotheses. 2006; 66(6):1248-1249.
20. The human hypothalamus in health and disease. Proceedings of the 17th International Summer School of Brain Research. Amsterdam, The Netherlands, 26-30 August, 1991. Prog Brain Res. 1992;93: 1-481.
21. Erickson D, Natt N, Nippoldt T, et al. Dexamethasone-suppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. J Clin Endocrinol Metab. 2007;92(8):2972-2976.
22. Martin NM, Dhillo WS, Banerjee A, et al. Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 2006;91(7):2582-2586.
23. Pecori Giraldi F, Pivonello R, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf). 2007;66(2):251-257.
24. Gatta B, Chabre O, Cortet C, et al. Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild Cushing's disease from pseudo-Cushing's syndrome. J Clin Endocrinol Metab. 2007;92(11):4290-4293.
25. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2006;29(5):471-482.
26. Rollin GA, Costenaro F, Gerchman F, Rodrigues TC, Czepielewski MA. Evaluation of the DDAVP test in the diagnosis of Cushing's Disease. Clin Endocrinol (Oxf). 2015;82(6):793-800.
27. Tsagarakis S, Vasiliou V, Kokkoris P, Stavropoulos G, Thalassinos N. Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity. Clin Endocrinol (Oxf). 1999;51(4):473-477.
28. Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C, Thalassinos N. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxf). 1998;49(2):165-171.
29. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab. 2002;87(12):5367-5384.
30. Majnik J, Patocs A, Balogh K, et al. Overrepresentation of the N363S variant of the glucocorticoid receptor gene in patients with bilateral adrenal incidentalomas. J Clin Endocrinol Metab. 2006; 91(7):2796-2799.
31. Heuser IJ, Gotthardt U, Schweiger U, et al. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging. 1994;15(2):227-231.
32. Reynolds RM. Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesis-2012 Curt Richter Award Winner. Psychoneuroendocrinology. 2013;38(1):1-11.